Highlights X4 Pharmaceuticals, Inc.

Equities

XFOR

US98420X1037

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
1.09 ^USD	-9.17%		-2.68%	+29.99%

May. 07	Transcript : X4 Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024
May. 07	X4 Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

X4 Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Pantherx® Rare Partner with X4 Pharmaceuticals Inc. for the Distribution of Xolremdi? (Mavorixafor), the First FDApproved Therapy Indicated for Use in Patients with Whim Syndrome	Apr. 29	CI
X4 Pharmaceuticals' Xolremdi Approved by FDA For WHIM Syndrome	Apr. 29	MT
X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome	Apr. 29	CI
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 21	CI
North American Morning Briefing : Investors -2-	Mar. 21	DJ
X4 Pharmaceuticals, Inc. Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023	Dec. 09	CI
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in Whim Syndrome	23-10-31	CI
X4 Pharmaceuticals Submits NDA to FDA for Mavorixafor to Treat WHIM Syndrome	23-09-05	MT
X4 Pharmaceuticals Announces Submission of New Drug Application to U.S. Fda for Mavorixafor in Whim Syndrome	23-09-05	CI
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
X4 Pharmaceuticals Set to Join Russell 3000; Shares Rise	23-06-13	MT
X4 Pharmaceuticals, Inc. Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Time of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome	23-05-16	CI
X4 Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
X4 Pharmaceuticals, Inc. Announces Late-Breaking Abstract of Whim Phase 3 Clinical Data Accepted for Oral Presentation At the 2023 Annual Meeting of the Clinical Immunology Society	23-04-12	CI
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-21	CI
X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia	22-12-12	CI
X4 Pharmaceuticals Reports 'Positive' Top-Line Data from Late-Stage Trial in WHIM Syndrome; Shares Fall	22-11-30	MT
X4 Pharmaceuticals Announces Positive Top-Line Results from 4Whim Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in Whim Syndrome	22-11-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights X4 Pharmaceuticals, Inc.

Equities

XFOR

US98420X1037

Highlights

Filters